J. PAUL YOUNG, M.D.
This report describes the results obtained in a group of 50 consecutive private patients with chronic rheumatoid arthritis who received chloroquine phosphate (Aralen) as the major medical agent in the management of their disease for 18 to 36 months. The average duration of treatment was 24 months. An analysis of the successes and failures in this group will be presented with the clinical, laboratory and radiological changes that occurred during treatment. A dose schedule was evolved which was found to give the best results to the greatest number of patients with the least incidence of side effects.
During an intensive
YOUNG JP. CHLOROQUINE PHOSPHATE (ARALEN) IN THE LONG-TERM TREATMENT OF RHEUMATOID ARTHRITIS(CHLOROQUINE PHOSPHATE (ARALEN) IN THE LONG-TERM TREATMENT OF RHEUMATOID ARTHRITIS*). Ann Intern Med. 1959;51:1159–1178. doi: 10.7326/0003-4819-51-6-1159
Download citation file:
Published: Ann Intern Med. 1959;51(6):1159-1178.
Geriatric Medicine, Rheumatoid Arthritis, Rheumatology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use